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Background: Transient symptoms in Alzheimer dis-
ease (AD) are frequent and include seizures, syncope, and
episodes of inattention or confusion. The incidence of
seizures in AD and predictors of which patients with AD
might be more predisposed to them is based primarily
on retrospective studies and is not well established.
Objective: To determine the incidence and predictors
of new-onset unprovoked seizures.
Design: Prospective cohort study.
Setting: Three academic centers.
Patients: Four hundred fifty-three patients with prob-
able AD observed prospectively frommild disease stages
since 1992.
Main Outcome Measure: Informant interviews ev-
ery 6 months included questions about whether the pa-
tient had a seizure (convulsion, fainting, or “funny” spell)
and whether diagnosis or treatment for epilepsy or sei-
zure was made. Two epileptologists independently ret-
rospectively reviewed all availablemedical records for 52
patients with positive responses to either of these ques-
tions, and using a specific checklist form, events were di-
agnosed as to whether they were unprovoked seizures
(intrarater concordance, =0.67). Diagnosis of unpro-
voked seizures constituted the event in survival analy-
ses. Potential predictors included sex, age, race/
ethnicity, educational achievement, duration of illness,
baseline cognition and function, depression, medical co-
morbidities, and time-dependent use of cholinesterase in-
hibitors and neuroleptic agents, apolipoprotein E geno-
type, and previous electroencephalographic findings.
Results:Over the course of 3518 visit-assessments (per
patient: mean, 7.8; maximum, 27), 7 patients (1.5%) de-
veloped seizures. Younger agewas associatedwith higher
risk (hazard ratio, 1.23; 95% confidence interval, 1.08-
1.41; P=.003 for each additional year of age) of seizure
incidence. No other predictor was significant. The over-
all incidence of seizureswas low (418 per 100 000 person-
years of observation) although significantly higher than
expected for idiopathic unprovoked seizures in similar
age ranges of the general population (hazard ratio, 8.06;
95% confidence interval, 3.23-16.61).
Conclusions: Unprovoked seizures are uncommon in
AD, but they do occur more frequently than in the gen-






ies have suggested that Alz-
heimer disease (AD)may be
a risk factor for seizures. Sei-
zures are common in various brain dis-
eases; however, differentiation between
nonepileptic and epileptic events may be
challenging. Patients with dementia may
experience nonepileptic episodes of inat-
tention or confusion as well as syncope or
near-syncope and seizures. Hospitaliza-
tionsmay ensue, and anticonvulsant agents
are often prescribed. The relationship of
epileptic activity to AD is of clinical im-
portance. In addition, it has been pro-
posed to relate to the pathogenesis of AD.
For example, according to the findings a
recent study by Palop et al,5 spontaneous
nonconvulsive seizure activity was noted
in a mouse model of AD.
Previous studies in human beings have
reported conflicting results about the
prevalence of seizures in dementia andAD,
with frequency ranging from 5% to
64%.2-4,6-13 Overall, data is scarce about sei-
zures in dementia andAD, and it is notwell
known which factors might contribute to
seizures. Most previous studies have been
small, with short follow-up, and have not
systematically recorded clinical charac-
teristics that may relate to seizure risk. In-
dividuals with dementia have been en-
rolled at varying disease stages, and clinical
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evaluations have typically been infrequent. Few studies
have examined the association prospectively. Dementia
characterization has not always been comprehensive, and
dementia diagnosis has not always been made in aca-
demic centers with experience with the disease. Clinical
characterization of seizure events has been variable aswell,
with many reports relying on medical record reviews or
assessments by nonepileptologists.
To investigate the issue of seizures in AD, we ana-
lyzed data from a largemulticenter study of patients with
probable AD followed up prospectively on a semian-
nual basis from the early stages of the disease for up to
14 years. We assessed the incidence of unprovoked sei-
zures and identified characteristics that predict them. A
recent publication from our group4 investigated these is-
sues in a small sample (“Predictors Study”14-16 I cohort).
This study is an extended evaluation of the incidence of
seizures in AD with particular attention to accurate
assessment of the nature of possible epileptic events.
We used a standardized checklist for review of events.
Independent review of all events was performed by 2
epileptologists (H.C. and J.C.). We also considered a
wide variety of potential seizure predictors. We mark-
edly increased our sample size by including both the
Predictors Study I and II cohorts and also had a longer




Individuals from 2 Predictors Study cohorts14-16 were included
in these analyses. Patients were recruited and studied at 3 sites:
Columbia University, New York, New York; The Johns Hop-
kins University, Baltimore, Maryland; andMassachusetts Gen-
eral Hospital, Harvard University, Boston. The inclusion and
exclusion criteria and the evaluation procedures of the Predic-
tors Study are fully described elsewhere.14-17 In brief, patients
metDiagnostic and StatisticalManual ofMental Disorders (Third
Edition Revised) criteria for primary degenerative dementia of
the Alzheimer type and National Institute of Neurological Dis-
orders and Stroke–AlzheimerDisease and RelatedDisorders As-
sociation criteria for probable AD. Enrollment required amodi-
fiedMini-Mental State Examination (MMSE) score of 30/57 or
higher, which is approximately equivalent to 16/30 or higher
on the Folstein MMSE.18,19 The study was approved by the lo-
cal institutional review boards.
EVALUATION
Neurologic, other clinical, andmental status examinationswere
conducted at study enrollment and at 6-month intervals there-
after. The cognitive functionmeasure used for the analysis was
the modified MMSE,18-20 a 57-point modification of the origi-
nalMMSE.18 Functional capacity was assessed using the Blessed
Dementia Rating Scale, parts 1 and 2.21 Depression recorded
using the Columbia University Scale for Psychopathology in
Alzheimer’s Disease22 was also used as a predictor.23 At every
6-month visit, medications taken by the patients were re-
corded. All cholinesterase inhibitors were grouped in a single
category and considered as a dichotomous variable in the analy-
ses,16,24 as were all neuroleptic agents.16,24 A modified ver-
sion15,16 of the Charlson Index of Comorbidity25 (referred to as
“comorbidity index”) was calculated and used in a dichoto-
mous form (0 [67%] vs 1 [33%]).
When data collectionwas initiated, apolipoprotein E (APOE)
testing was unavailable; however, beginning in the sixth year
of the study, the pattern of APOE isoforms was determined26
and considered in the analyses. An electroencephalogram (EEG)
was not required but was obtained in a subset of patients as
part of the routine dementia workup at or before the baseline
visit. The EEG reports were coded dichotomously on the basis
of specific criteria for slow dominant rhythm, focal slowing,
intermittent rhythmic slowing, other slowing, focal epilepti-
form activity, and generalized epileptiform activity.
OUTCOMES
The questions in the original database addressing the occur-
rence of a seizure were as follows: “In the past 6 months, has
the patient been diagnosed or treated for epilepsy or sei-
zures?” and “Has the patient had a seizure (fit, faint, or funny
spell) since the last visit?” This information was recorded at
baseline and at every 6-month evaluation thereafter. To assess
the likelihood of an event being a seizure, 2 epileptologists (H.C.
and J.C.) independently retrospectively reviewed the original
questionnaires and all availablemedical records (including clini-
cal and EEG data) for 52 patients with an affirmative answer
to either of the 2 questions in any evaluation. Each epileptolo-
gist’s conclusion about the epileptic nature of the event (rated
dichotomously as “likely in the presence of adequate informa-
tion vs unlikely or uncertain”) was used for diagnostic agree-
ment calculation. The 2 epileptologists convened and reached
a consensus diagnosis if their opinions varied about the like-
lihood of a seizure. This consensus diagnosis of unprovoked
seizures was used for final seizure calculation.
STATISTICAL ANALYSES
We calculated the  statistic to examine unprovoked seizure
diagnostic concordance between the 2 epileptologists.We used
the Kaplan-Meier method to calculate survival curves for the
development of unprovoked seizures (outcome) in patientswho
were seizure free at the baseline assessment. The duration be-
tween the initial visit and either development of a seizure or
last evaluation without a seizure (ie, death or last follow-up)
served as the timing variable. Because we did not have a con-
trol population without AD, age-specific incidence in 10-year
age groups was calculated and compared with age-specific in-
cidence in a referent cohort,27,28 resulting in incidence ratios.
To identify potential predictors of seizure incidence, we cal-
culated Cox proportional hazards models29 with the following
predictors: cohort (Predictors Study I vs II cohorts; dichoto-
mous), recruitment center (dummy variable with theNewYork
center as reference), sex (male as reference), age at intake
(years), race/ethnicity (dummy variable with white as refer-
ence), educational achievement, estimated duration of illness,
baseline function (Blessed Dementia Rating Scale), cognition
(modified MMSE), depression, medical comorbidities (co-
morbidity index), and time-dependent use of cholinesterase
inhibitors and neuroleptic agents. In supplementary models,
we included patient APOE genotype and EEG variables as ad-
ditional predictors.
RESULTS
Overall, 453 patients with ADwere included in the study,
with approximately half from each Predictors Study co-
hort (Table). As dictated by the inclusion criteria, pa-
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tients were at relatively early stages of AD at initial re-
cruitment (meanMMSE score, 21). Theywere, on average,
well educated and in good general health (approxi-
mately two-thirds had a comorbidity index of 0). Most
patients were white. About half of the patients reported
some symptoms of depression.23
SEIZURE SCREENING QUESTION
Fifty-two of 453 patients (11.5%) gave at least 1 positive
response to the seizure-related questions. Compared with
401 patients without any positive response, the 52 with at
least 1 positive responsewere younger (74.9 vs 70.7 years;
t=3.3; P=.001). The groups did not differ in recruitment
cohort or center, sex, race/ethnicity, educational achieve-
ment, baseline cognitive performance, functional status, es-
timated duration of illness, APOE genotype, mortality or
institutionalization risk during follow-up, or presence of
depression or medical comorbidities.
Autopsy data were available for 90 patients (75 of the
401 patients without any positive response to the seizure-
related questions and 15 of the 52 patients with at least
1 positive response). At autopsy, all 15 patients with at
least 1 positive response to the seizure-related ques-
tions had AD-type pathologic changes and none had
pathologic changes consistent with hippocampal sclero-
sis. Lewy bodies were present in addition to AD patho-
logic findings in 27 of 75 patients (36%)without any posi-
tive response to the seizure-related questions and in 4
of 15 (27%)with at least 1 positive response to the seizure-
related questions (P=.49).
SEIZURE DIAGNOSTICS
Among 52 patients with at least 1 positive response to
the seizure-related questions, 7 (13%) were deemed by
consensus to have had epileptic events (approximately
1.5% of 453 patients). The EEG reports were available
for the epileptologists’ review for 21 of 52 patients (40%).
Among those with available EEGs, findings were com-
pletely normal in 38%, diffuse slowingwas noted in 38%,
focal slowing in 20%, and epileptiform activity in 16%.
The 2 epileptologists were in diagnostic agreement for
48 of the 52 patients (5 deemed to have and 43 deemed
not to have events of an eplipetic nature). There was an
initial diagnostic discordance for 4 patients: 2 were con-
sidered to have had seizures by 1 epileptologist (J.C.) but
not by the other (H.C.), and 2 were considered to have
had seizures by 1 epitologist (H.C.) but not by the other
(J.C.). The overall  statistic was 0.67, denoting good di-
agnostic reproducibility.30 Insofar as seizure semiology,
changes in level of attention were noted in all 7 pa-
tients, andwhole-body convulsion in 6. Twopatients dem-
onstrated clinical semiology of lateralized findings; 3
events led to hospitalization, and 5 patients were treated
with antiepileptic medications. Four patients had only a
single seizure, and 3 had more than 1 seizure. Data only
for patients who were seizure free at the baseline assess-
ment were used for seizure incidence calculation. Con-
sidering patient-estimated duration of illness before en-
rollment in the study, seizures occurred at a mean (SD;
range) of 8.2 (2.6; 5.1-11.8) years after estimated clini-
cal onset of AD and 3.7 (3.1) years after recruitment into
the study.
Among the 45 patients-events not rated by the epi-
leptologists as being of an epileptic nature, 9 (17%) were
classified as “very unlikely to be epileptic in the pres-
ence of good information for diagnostic assignment,” and
36 (69%) were classified as of “uncertain diagnostic as-
signment because of inadequate information.” Com-
pared with 45 patients whose events were not convinc-
ing of an epileptic nature, the 7 judged to have had seizures
were younger (71.9 vs 62.9 years; t=2.85; P=.006). These
groups did not differ in recruitment cohort or center, sex,
race/ethnicity, educational achievement level, baseline
cognitive performance, functional status, estimated du-
ration of illness, APOE genotype, mortality or institu-
tionalization risk during follow-up, or presence of de-
pression or medical comorbidities.
Autopsy data were available for 11 of the 45 patients
whose events were not considered of an epileptic nature
and for 4 of the 7 subjects deemed to have had seizures
(all of the 15 autopsied subjects had AD-type patho-
logic changes, andnone hadhippocampal sclerosis). Lewy
bodies were present in 3 of 11 patients (27%)with events
that were not considered of an epileptic nature and in 1
of 4 patients (25%) with seizures (P=.93).
Table. Demographic and Clinical Characteristics
of 453 Patients
Variable Value
Age at study enrollment, mean (SD), y 74.4 (8.9)
Men, No. (%) 181 (40)
Predictors Study cohort I, No. (%) 247 (55)
Recruitment center, No. (%)
New York, New York 197 (43)
Baltimore, Maryland 139 (31)





Educational achievement, mean (SD), y 13.7 (3.5)
Examination score
Baseline mMMSE, mean (SD) 38.4 (6.7)
Baseline MMSE, mean (SD) 21.0 (3.3)
Baseline BDRS, mean (SD) 3.6 (2.0)
Duration of illness, mean (SD), y 4.1 (2.4)
Comorbidity index 1 (%) 150 (33)
Depression, No. (%) 208 (46)
ε4 Alleles, No. (%)
None 77 (45)
1-2 93 (55)
EEG findings,a No. (%)
Slow dominant rhythm 55 (29)
Focal slowing 22 (12)
Intermittent rhythmic slowing 10 (5)
Other slowing 51 (28)
Focal epileptiform 5 (3)
Generalized epileptiform 2 (1)
Abbreviations: BDRS, Blessed Dementia Rating Scale; EEG,
electroencephalographic; MMSE, Mini-Mental State Examination; mMMSE,
modified MMSE.
an=184.
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SEIZURE RATES
Patients were followed up on average for 3.7 (up to 14)
years, during which time there were 3518 visit-
assessments (on average, 7.8; as many as 27 per pa-
tient). During the period that each subject was followed
up, missed visits were rare: less than 18% missed more
than 1 semiannual visit, and less than 9% missed more
than 2 semiannual visits. Cumulative incidence of new-
onset seizures (n=7 over 1674 person-years of observa-
tion) was 418 per 100 000 person-years of observation
(Figure). Assuming a stable rate over time and no in-
creasing risk with increasing severity, this would corre-
spond to approximately 2% of patients with AD devel-
oping seizures after 5 years of follow-up. Compared with
the rate of unprovoked seizures in the general popula-
tion of similar age strata,27,28 this incidence was higher
than expected (incidence ratio, 8.06; 95% confidence in-
terval [CI], 3.23-16.61).
In sensitivity analyses of 43 patients, we considered
as patients with seizures not only the 7 patients with a
consensus diagnosis of seizures but also the 36 classi-
fied as having uncertain diagnostic assignment because
of inadequate information. Cumulative incidence of new-
onset seizures (n=43 over 1602 person-years of obser-
vation) was 2684 per 100 000 person-years of observa-
tion. Assuming a linear risk over time, this would
correspond to approximately 13% of patients with AD
developing seizures after 5 years of follow-up. Com-
pared with the rate of unprovoked seizures in the gen-
eral population of similar age strata,27,28 this incidence
was higher than expected (incidence ratio, 49.43; 95%
CI, 37.58-69.96).
In a Cox model considering cohort, recruitment
center, sex, age, race/ethnicity, educational achieve-
ment, estimated duration of illness, baseline function, cog-
nition, depression, medical comorbidities, and time-
dependent use of cholinesterase inhibitors andneuroleptic
agents, only younger age was associated with higher risk
of seizures (hazard ratio for each additional year of age,
1.23; 95%CI, 1.08-1.41;P=.003), corresponding to a 23%
increased risk. In a supplementary model including pa-
tient APOE genotype as an additional predictor (6 inci-
dent seizure events in 157 patients), the associationswere
similar, with younger age being the only predictor of in-
creased seizure risk (hazard ratio, 1.22; 95% CI, 1.01-
1.47; P=.04). In a supplementarymodel considering also
the EEG variables as additional predictors (6 incident sei-
zure events in 169 patients), younger age was the only
significant predictor of increased seizure risk (for each
additional year of age: hazard ratio, 1.39; 95% CI, 1.03-
1.85; P=.03).
COMMENT
Our study supports previous reports1-4 that suggested that
AD is a risk factor for seizures. However, we also ob-
served that seizures are not common in AD. In our study,
only about 1.5% of patients with AD developed seizures
over the course of a mean of 3.7 years of follow-up. Most
seizures were generalized convulsions and nonrecur-
rent. The observed incidence corresponds to less than 1
patient with a seizure for every 200 patients with AD fol-
lowed up over the course of 1 year. Therefore, we con-
clude that although seizures are more common in pa-
tients with AD compared with the general population,
they are a quite uncommon feature of AD.
Some studies have concluded that seizures occur in
themore advanced stages of the disease.3,9,12 In our study,
we did not detect an association between seizures and
either estimated disease duration or cognitive or func-
tional performance. Lack of association between patient
age at AD onset and seizures3 or higher risk of seizures
in younger patientswith ADhas been noted in other stud-
ies, including one from the Predictors Study I cohort.4
Younger patients with ADmay havemore aggressive dis-
ease31 or may be more likely to have a clinical episode
recognized; alternatively, the younger brainmay bemore
susceptible to seizure manifestation.
Unlike our group’s previous report from the Predic-
tors Study,4 in the present study, we did not observe an
association between seizure risk and either EEG find-
ings or race/ethnicity. Differences between the previous
and the present article include the following. The pres-
ent analyses are much more powerful because we
included more than twice as many patients with AD
(Predictors Study) with data from additional years of
follow-up.We also examined potential seizure events in a
more conservative and detailed manner using 2 indepen-
dent epileptologists and consensus diagnostic proce-
dures. These differences resulted in a lower seizure rate.
In addition, we considered in our analyses more potential
predictors such as multiple additional EEG variables, ad-
ditionalmedical comorbidities,measures of functional sta-
tus, use ofmedications such as neuroleptic agents and cho-
linesterase inhibitors, and autopsy information.
This study has several limitations. Patients with AD
were selected from tertiary care university hospitals and
specialized diagnostic and treatment centers and, thus,
constitute a nonrandom sample of those affected by AD
in the population. The percentage of African American
and Hispanic patients in our sample was small, and our
results might not be generalizable to all racial/ethnic



























Figure. Survival curve based on Kaplan-Meier analysis depicts cumulative
seizure incidence.
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on incidence of unprovoked seizures from a different
population. Routine EEGswere available for only a small
percentage of the patients, and the EEG yield insofar as
detection of underlying epileptiformactivitymay vary sub-
stantially.32 A large-scale epidemiologic study such as this
can only address seizures that are clinically evident but
cannot evaluate subclinical epileptic activity. In particu-
lar, partial seizures without convulsive components or
with more subtle alterations in attention and alertness
may have been underrecorded. Despite thorough re-
view of available records, information for reliable diag-
nostic assignment of events as epileptic or not was miss-
ing in a substantial number of subjects. Hence, it is
conceivable that considering only patients with convinc-
ing clinical information for seizure diagnosis may un-
derestimate the rates of seizure occurrence. In addition,
despite expertise in seizure diagnosis, diagnostic con-
cordance between epileptologists was good but not ex-
cellent. In the absence of an objective diagnostic marker
for seizures, there is always a strong subjective compo-
nent in seizure characterization, and different diagnos-
tic thresholds may result in different seizure rate esti-
mations (as demonstrated in the sensitivity analyses).
Although most of the information was derived by infor-
mants, description of epileptic semiologymay be less re-
liable in individuals with dementia; however, even pa-
tients with epilepsy without dementia have major
difficulties in describing seizure experiences or accu-
rately reporting seizure frequency,33 in particular for com-
plex or generalized seizures. These factors may lead to
seizure underestimation. In contrast, fluctuations in alert-
ness and attention and presence of tremor (phenomena
common in dementia) may lead to seizure overestima-
tion. For similar reasons, seizure rates in the general popu-
lationmay substantially vary; therefore, the choice of ref-
erent populationmay also affect the calculated incidence
ratios. Although patient follow-up and seizure-related
screening questions were prospective, clinical evalua-
tion for the epileptic nature of the event was retrospec-
tive. Because of the small number of autopsies per-
formed, our power to detect associationswith Lewybodies
or hippocampal sclerosis may have been limited.
Confidence in our findings is strengthened by sev-
eral factors. To our knowledge, this is the largest study
of its kind to examine the issue of seizures in AD, sup-
plying enough power for detection andmore precise cal-
culation of effects of interest and ability to control for
multiple potential confounders. Clinical diagnosis oc-
curred in university hospitals with specific expertise in
epilepsy and dementia and was based on uniform appli-
cation of widely accepted criteria via consensus diagnos-
tic conference procedures for both diseases. In the Pre-
dictors Study I and II cohorts, the clinical diagnosis of
AD was confirmed in a high percentage (93%) of those
evaluated postmortem14,16; it was also confirmed in ev-
ery autopsy case with positive response to the seizure-
related questions. The patients were followed up pro-
spectively, and evaluationswere performed semiannually
with a high rate of follow-up participation and fewmiss-
ing data. Clinical symptoms and signs of interest were
ascertained and coded in a standardized fashion at each
visit. Patients with ADwere included from relatively early
stages of the disease; thus, the cohort captures most of
the range of progression over time. We took medication
administration into account in a time-dependent man-
ner, which provides higher confidence that the associa-
tions are strictly related to the underlying disease pro-
cess rather than to treatment for it.
Alzheimer disease is an illness with considerable clini-
cal and physiologic heterogeneity.14,16,34-36 Although sei-
zures do occur in AD, the present study indicates that
they are not a common phenomenon.
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